Compare Stocks: TIL, ORMP, ALXO, and PEPG

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$1.06 +6.0%	$1.68	$0.86 ▼ $2.66	$138.28M	0.47	1.69 million shs	2.43 million shs
ORMP Oramed Pharmaceuticals	$4.07 -2.6%	$4.65	$2.09 ▼ $5.47	$173.88M	1.29	173,963 shs	277,085 shs
PEPG PepGen	$2.60 +2.8%	$2.83	$1.31 ▼ $7.80	$175.23M	2.01	846,373 shs	1.20 million shs
TIL Instil Bio	$5.91 -3.6%	$7.23	$5.67 ▼ $20.33	$41.57M	1.94	23,034 shs	25,172 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	+6.00%	-15.20%	-39.77%	-49.52%	-36.14%
ORMP Oramed Pharmaceuticals	-2.63%	-6.00%	-11.90%	+0.99%	+79.30%
PEPG PepGen	+2.77%	-0.76%	-10.34%	+15.56%	-46.83%
TIL Instil Bio	-3.59%	-12.31%	-17.69%	-20.35%	-71.99%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$1.06 +6.0%	$1.68	$0.86 ▼ $2.66	$138.28M	0.47	1.69 million shs	2.43 million shs
ORMP Oramed Pharmaceuticals	$4.07 -2.6%	$4.65	$2.09 ▼ $5.47	$173.88M	1.29	173,963 shs	277,085 shs
PEPG PepGen	$2.60 +2.8%	$2.83	$1.31 ▼ $7.80	$175.23M	2.01	846,373 shs	1.20 million shs
TIL Instil Bio	$5.91 -3.6%	$7.23	$5.67 ▼ $20.33	$41.57M	1.94	23,034 shs	25,172 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	+6.00%	-15.20%	-39.77%	-49.52%	-36.14%
ORMP Oramed Pharmaceuticals	-2.63%	-6.00%	-11.90%	+0.99%	+79.30%
PEPG PepGen	+2.77%	-0.76%	-10.34%	+15.56%	-46.83%
TIL Instil Bio	-3.59%	-12.31%	-17.69%	-20.35%	-71.99%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	333.96% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A
PEPG PepGen	2.67	Moderate Buy	$11.40	338.46% Upside
TIL Instil Bio	1.67	Reduce	$7.00	18.44% Upside

Current Analyst Ratings Breakdown

Latest TIL, ORMP, ALXO, and PEPG Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/22/2026	PEPG PepGen	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/17/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/9/2026	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/8/2026	ORMP Oramed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold (C+)
9/2/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/28/2026	PEPG PepGen	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
8/19/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$0.48 per share	N/A
ORMP Oramed Pharmaceuticals	$2M	84.66	$0.09 per share	46.07	$5.02 per share	0.81
PEPG PepGen	N/A	N/A	N/A	N/A	$2.14 per share	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	$16.79 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$101.69M	-$1.13	N/A	N/A	N/A	N/A	-90.30%	-67.28%	11/6/2026 (Estimated)
ORMP Oramed Pharmaceuticals	$64.05M	$4.12	0.99	N/A	N/A	N/A	-5.17%	-4.54%	11/12/2026 (Estimated)
PEPG PepGen	-$89.65M	-$1.31	N/A	N/A	N/A	N/A	-51.01%	-43.49%	11/11/2026 (Estimated)
TIL Instil Bio	-$71.37M	-$4.47	N/A	N/A	N/A	N/A	-26.78%	-14.89%	11/16/2026 (Estimated)

Latest TIL, ORMP, ALXO, and PEPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	ORMP Oramed Pharmaceuticals	$0.43	N/A	N/A	N/A	N/A	N/A
11/11/2026	Q3 2026	PEPG PepGen	-$0.27	N/A	N/A	N/A	N/A	N/A
11/6/2026	Q3 2026	ALXO ALX Oncology	-$0.15	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	TIL Instil Bio	-$0.35	-$0.63	-$0.28	-$0.63	N/A	N/A
8/10/2026	Q2 2026	ORMP Oramed Pharmaceuticals	$0.43	-$0.09	-$0.52	$1.84	N/A	N/A
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A
8/6/2026	Q2 2026	PEPG PepGen	-$0.2845	-$0.26	+$0.0245	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	$0.25	6.15%	N/A	6.07%	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.07	9.71	9.71
ORMP Oramed Pharmaceuticals	N/A	4.98	4.98
PEPG PepGen	N/A	13.36	13.36
TIL Instil Bio	0.79	21.67	21.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
ORMP Oramed Pharmaceuticals	12.73%
PEPG PepGen	58.01%
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	12.40%
ORMP Oramed Pharmaceuticals	20.77%
PEPG PepGen	1.30%
TIL Instil Bio	47.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	48	138.28 million	121.13 million	Optionable
ORMP Oramed Pharmaceuticals	13	41.60 million	32.96 million	Optionable
PEPG PepGen	57	69.26 million	68.36 million	Not Optionable
TIL Instil Bio	410	6.78 million	3.59 million	No Data

TIL, ORMP, ALXO, and PEPG Headlines

Recent News About These Companies

5 Biotech Stocks Worth Adding to Your Portfolio Now

August 26, 2026 | zacks.com

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 13, 2026 | globenewswire.com

Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)

July 16, 2026 | seekingalpha.com

Instil Bio Shareholders Back Directors and Auditor at Meeting

June 11, 2026 | tipranks.com

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 15, 2026 | globenewswire.com

Instil Bio (TIL) Price Target Increased by 24.53% to 67.32

April 9, 2026 | msn.com

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 27, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

February 12, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

February 3, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 29, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio,

January 27, 2026 | bakersfield.comB

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 27, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 22, 2026 | prnewswire.com

TIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & Korsinsky

January 20, 2026 | newsfilecorp.comN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 20, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 15, 2026 | prnewswire.com

Instil Bio (TIL) Price Target Decreased by 45.17% to 53.55

January 14, 2026 | msn.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 13, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 8, 2026 | prnewswire.com

HC Wainwright & Co. downgrades Instil Bio (TIL)

January 8, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TIL, ORMP, ALXO, and PEPG Company Descriptions

ALX Oncology NASDAQ:ALXO

$1.06 +0.06 (+6.00%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$1.06 +0.00 (+0.47%)

As of 10/16/2026 07:57 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Oramed Pharmaceuticals NASDAQ:ORMP

$4.07 -0.11 (-2.63%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$4.08 +0.01 (+0.25%)

As of 10/16/2026 07:30 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

PepGen NASDAQ:PEPG

$2.60 +0.07 (+2.77%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$2.59 -0.01 (-0.38%)

As of 10/16/2026 07:58 PM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

Instil Bio NASDAQ:TIL

$5.91 -0.22 (-3.59%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$5.95 +0.04 (+0.74%)

As of 10/16/2026 07:30 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TIL, ORMP, ALXO, and PEPG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TIL, ORMP, ALXO, and PEPG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TIL, ORMP, ALXO, and PEPG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TIL, ORMP, ALXO, and PEPG Company Descriptions

ALX Oncology NASDAQ:ALXO

Oramed Pharmaceuticals NASDAQ:ORMP

PepGen NASDAQ:PEPG

Instil Bio NASDAQ:TIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TIL, ORMP, ALXO, and PEPG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TIL, ORMP, ALXO, and PEPG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TIL, ORMP, ALXO, and PEPG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TIL, ORMP, ALXO, and PEPG Company Descriptions

ALX Oncology NASDAQ:ALXO

Oramed Pharmaceuticals NASDAQ:ORMP

PepGen NASDAQ:PEPG

Instil Bio NASDAQ:TIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools